含吡啶的抗肿瘤转移NAMI-A衍生物的制备和水解机理动力学

目的研究配体结构对NAMI-A衍生物水解机理、电化学性质的影响。方法制备了trans-[RuCl4(DMSO)(3-MePy)][(3-MePy)H](3-MePy=3-甲基吡啶,化合物1)和trans-[RuCl4(DMSO)(4-MePy)][(4-MePy)H](4-MePy=4-甲基吡啶,化合物2)。用UV、NMR、CV法研究化合物1、化合物2的水解机理-动力学、溶液稳定性及电化学性质。结果化合物1和化合物2与NAMI-A相似,在pH7.40的缓冲液中发生脱氯水解反应(Ⅰ氯水解及Ⅱ氯水解)(分步反应);在pH 5.00缓冲液中DMSO(二甲亚砜)及少量吡啶水解。测定各水解反应表观速率常数及半衰期、溶液稳定性及氧化还原电位。结论化合物1、化合物2的Ⅰ氯、Ⅱ氯及DMSO水解反应机理与NAMI-A相似,而且各水解速率与NAMI-A相差不大,即用甲基吡啶取代咪唑环,对NAMI-A衍生物的Ⅰ氯、Ⅱ氯及DMSO水解反应速率影响较小。化合物在酸性溶液中的稳定性明显高于中性溶液。     

含4-乙基吡啶的抗转移NAMI、NAMI-A衍生物的水解动力学及稳定性研究

制备了trans-[RuCl4(DMSO)(4-EtPy)]Na·2DMSO(4-EtPy=4-乙基吡啶)(化合物1)和trans-[RuCl4(DMSO)(4-EtPy)][(4-EtPy)H](化合物2).用UV、NMR研究了化合物在pH 7.40及5.00(0.15 mol·L-1 NaCl,37℃)缓冲液中的水解机理-动力学和溶液稳定性.测得各水解反应表观速率常数、半衰期.研究结果表明:两个化合物的Ⅰ氯、Ⅱ氯及DMSO水解反应机理均与NAMI-A相似,但其各级水解速率比NAMI-A略快,即用4-EtPy取代咪唑环,可加快NAMI-A衍生物的Ⅰ氯、Ⅱ氯及DMSO水解反应速率.在含氮配体相同时,NAMI-A衍生物比相应NAMI衍生物的稳定性稍好.化合物在酸性溶液中的稳定性高于中性溶液.提供了用核磁法定量测定NAMI-A衍生物的水解机理-动力学.     

手性锌卟啉对咪唑类客体的分子识别及圆二色光谱的研究

研究了手性α,α,α,β－四－[邻（叔丁氧羰L－酪氨酸）氨基苯基]卟啉 锌[α,α,α,β-ZnT(o-Boc)TyrTAPP](1)和手性α,α,α,β－四－[邻（叔 丁氧羰L－丙氨酸）氨基苯基]卟啉锌[α,α,α,β-ZnT(o-BocAla)TAPP](2)对 咪唑、2－甲基咪唑、N－甲基咪唑和2－乙基－4－甲基咪唑的分子识别行为,分别 求得主体（1）对咪唑类分子识别的缔合常数顺序为K（Im)>K(2-MeIm)>K(N-MeIm) >K(2-Et-4-MeIm),主体（2）对咪唑类分子识别的缔合常数顺序为K（2－MeIm)>K (Im)>K(2-Ek-4-MeIm)>K(N-MeIm),并用圆二色光谱（CD）研究了主体1和2对咪唑 在客体在CHCl3中分子识别的光谱行为,与热力学的结果做了比较。     

配体结构对含2-甲基咪唑及N-乙基咪唑的NAMI 衍生物水解及溶液稳定性的影响

制备并用UV、循环伏安(CV)和NMR 法研究了NAMI(新抗肿瘤转移抑制剂, trans-[RuCl₄(DMSO)(imidazole)]Na·2DMSO)衍生物trans-[RuCl₄(DMSO)(2-MeIm)]Na·2DMSO (2-MeIm＝2-甲基咪唑, 化合物1)和trans-[RuCl₄(DMSO)-(N-EtIm)]Na·2DMSO (N-EtIm＝N-乙基咪唑, 化合物2)的水解机理-动力学、溶液稳定性和电化学性质. 化合物1 和化合物2 与NAMI 相似, 在pH 7.40 的缓冲溶液中发生两步脱氯水解反应(I 氯水解及II 氯水解) (分步反应); 在酸性溶液(pH 5.00)中脱DMSO 水解. 通过线性拟合得到各水解反应速率常数k_obs 及半衰期t_1/2. 结果表明化合物在酸性溶液中的稳定性相对较高. 在NAMI 衍生物咪唑环的N 位引入乙基比在2 位引入甲基生成的化合物稳定. 含氮配体相同时,NAMI-A(新抗肿瘤转移抑制剂, A: 该系列中的第一个化合物, trans-[RuCl₄(DMSO)(imidazole)][Himidazole])衍生物略比相应的NAMI 衍生物稳定.     

新型Salen型配合物的合成和表征及轴向配位热力学

采用金属模板法合成了四个新型Salen型单、双核金属配合物,并用元素分析、核磁共振(1HNMR)、电喷雾质谱(ESI-MS)、傅里叶变换红外光谱(FT-IR)等手段进行了表征.使用紫外-可见(UV-Vis)光谱滴定法和圆二色(CD)光谱研究了主体金属镍配合物与咪唑类含氮小分子的轴向配位反应热力学性质.结果表明:主体与咪唑(Im)和N-甲基咪唑(N-MeIm)的配位数是2,而与2-Et-4-MeIm和2-MeIm的配位数是1;轴配体系的热力学数据显示主体与咪唑类配体的平衡常数按K苓(Im)K苓(N-MeIm)K苓(2-Et-4-MeIm)K苓(2-MeIm)顺序依次减小;测得的△rHm苓和△rSm苓数据表明该轴向配位反应为放热、熵增加过程.     

两个由双咪唑基配体构筑的锰、镉配合物的合成及晶体结构(英文)

通过水热法合成了2个金属-有机配位聚合物[Mn(dipha)(1,3-bix)]n·nH2O(1)和[Cd2(NIPH)2(bimb)2.5(H2O)]n·3nH2O(2)(H2dipha=2,2′-联苯二甲酸,1,3-bix=1,3-双(咪唑基-1-甲基)-苯,H2NIPH=5-硝基间苯二甲酸,bimb=1,4-双(咪唑基-1-甲基)-丁烷)。并对其进行了元素分析、红外光谱、热重和X-射线单晶衍射测定。这2个配合物通过氢键和π-π相互作用形成了超分子网状结构。此外还研究了配合物2的荧光性质。     

基于两个取代四甲基环戊二烯基配体的金属羰基化合物的合成及晶体结构(英文)

配体[C5Me4HR][R=4-Br Ph(1),(Me C5H3N)CH2(2)]分别与Mo(CO)6,Ru3(CO)12和Fe(CO)5在二甲苯中加热回流,得到了6个双核配合物trans-[η5-C5Me4R]2Mo2(CO)6(3,4),trans-[(η5-C5Me4R)Ru(CO)(μ-CO)]2(5,6)和trans-[η5-(C5Me4R)Fe(CO)(μ-CO)]2(7,8)。通过元素分析、红外光谱、核磁共振氢谱对配合物的结构进行了表征,并用X-射线单晶衍射法测定了配合物3,5,6和8的结构。     

一个新型钌(Ⅱ)配合物对F~-的双重光谱识别

采用紫外-可见光谱和荧光光谱滴定方法研究了钌(Ⅱ)配合物[Ru(bpy)(H2iip)2](ClO4)2[bpy=2,2'-联吡啶,H2iip=2-吲哚基-咪唑并[4,5-f][1,10]-邻菲罗啉]在DMSO溶液中对卤素离子的识别性质.结果表明该配合物能比色和荧光双重光谱高选择性识别F-.     

手性Salen金属配合物与咪唑类客体分子识别的研究

用光谱滴定法研究了手性Salen金属配合物(SalenFe~(III), SalenCo~(II))与 四种咪唑类客体在CH_2Cl_2中的分子识别行为，发现手性Salen金属配合物与咪唑 ，N－甲基咪唑，2－甲基咪唑的配位数为2，与克霉唑的配位数为1。各识别体系缔 合常数的顺序对SalenFe~(III)为: K(Im) > K(2-MeIm) > K(N-MeIm) > K(GMZ)， 对SalenCo~(II)为：K(Im) > K(2-MeIm) > K(N-MeIm)。测定的识别反应的△ _rG_m~0, △_rH_m~0, △_rS_m~0表明此类识别反应为放热、熵减少的过程，反应 体系存在焓－熵补偿关系。采用分子力学和量子化学方法进行的理论研究对实验结 果作出了合理的解释。     

杂金属杯[4]配位聚合物的合成与表征（英文）

合成了4个杂金属杯[4]配位聚合物{[Cd(L)(tpa)]·3H_2O}n(1),{[Zn_2(L)_2(tpa)_2]·3H_2O}n(2),{[Co(L)(oba)]·2DMA·0.5H_2O}_n(3)和{[Zn(L)(oba)]·DMA}n(4)(L=2-(1H-咪唑基-甲基)-6-(3-(1H-咪唑基-甲基)-5-叔丁基-2-羟基)苄基-4-叔丁基苯酚,H2tpa=对苯二甲酸,H2oba=4,4′-二苯醚二甲酸),并通过元素分析、热重、红外光谱、固态紫外、单晶X射线衍射和粉末X射线衍射对其进行了表征。单晶结构分析表明晶体1是单斜晶系,P21/n空间群,而晶体2,3和4均为三斜晶系,P1空间群。化合物1,2,3和4是由0维[M(N_4O_2C_(29)H_(36))](M=Zn,Co,Cd)的杂金属杯[4]与配体对苯二甲酸和4,4′-二苯醚二甲酸形成的一维配位聚合物。     

A controlled NO-releasing compound: synthesis,molecular structure,spectroscopy, electrochemistry,and chemical reactivity of R,R,S,S-trans-[RuCl(NO)(cyclam)]2+(1,4,8,11-tetraazacyclotetradecane)

The synthesis of trans-[RuCl(NO)(cyclam)]2+ (cyclam = 1,4,8,11-tetraazacyclotetradecane) can be accomplished by either the addition of cyclam to K2[RuCl5NO] or by the addition of NO to trans-[RuCl(CF3SO3)(cyclam)](CF3-SO3). Crystals of trans-[RuCl(NO)(cyclam)](ClO4)2 form in the monoclinic space group P2(1)/c, with unit cell parameters of a = 7.66500(2) A, b = 24.7244(1) A, c = 16.2871(2) A, beta = 95.2550(10) degrees, and Z = 4. One of the two independent molecules in the unit cell lies disordered on a center of symmetry. For the ion in the general position, the Ru-N and N-O bond distances and the [Ru-N-O]3+ bond angle are 1.747(4) A, 1.128(5) A, 178.0(4) degrees, respectively. In both ions, cyclam adopts the (R,R,S,S) configuration, which is also consistent with 2D COSY 1H NMR studies in aqueous solution. Reduction (E degree = -0.1 V) results in the rapid loss of Cl- by first-order kinetics with k = 1.5 s-1 and the slower loss of NO (k = 6.10 x 10(-4) s-1, delta H++ = 15.3 kcal mol-1, delta S++ = -21.8 cal mol-1 K-1). The slow release of NO following reduction causes trans-[RuCl(NO)(cyclam)]2+ to be a promising controlled-release NO prodrug for vasodilation and other purposes. Unlike the related complex trans-[Ru(NO)(NH3)4(P(OEt)3)](PF6)2, trans-[RuCl(NO)(cyclam)]Cl2 is inactive in modulating evoked potentials recorded from mice hippocampal slices probably because of the slower dissociation of NO following reduction.     

Synthesis, characterization, and reactivity of ruthenium diene/diamine complexes including catalytic hydrogenation of ketones

Thermal reactions between [RuCl2(diene)]n (diene = 2,5-norbornadiene, nbd; 1,5-cyclooctadiene, cod) with an excess of N,N,N',N'-tetramethylethylene diamine (tmeda) afforded derivatives [RuCl2(diene)(tmeda)] (diene = nbd, 1; cod, 2) as a mixture of cis and trans isomers. When thermolysis was performed under H2 mixtures of hydride species [RuCl(H)(diene)(tmeda)] (diene = nbd, 3; cod, 4) and the bis-tmeda adduct trans-[RuCl2(tmeda)2] (5) were obtained in different ratios depending upon the reaction conditions and reaction times. Heating polymeric Ru(II) precursors in toluene in the presence of a 5-fold excess of the bulkier N,N,N',N'-tetraethylethylene diamine (teeda) resulted in a rare diamine dealkylation process with formation of trans-[RuCl2(nbd)(Et2NCH2CH2NHEt)] (6) and trans-[RuCl2(cod)(EtHNCH2CH2NHEt)] (7) in high yields. The presence of N-H functionalities in the coordinated diamine ligands of 6 and 7 was unambiguously established by single-crystal X-ray diffraction studies. The dealkylation process of the teeda ligand seems to proceed intramolecularly as shown by solution NMR studies performed with the soluble Ru(II) precursors trans-[RuCl2(amine)2(diene)] (diene = nbd, amine = morpholine, 9; diene = cod, amine = Et2NH, 10). The above complexes [RuCl2(diene)(diamine)] have been tested as precatalysts in the hydrogenation of ketones both for transfer as well as direct hydrogenation, the latter route being the most effective.     

Synthesis of nitrosylruthenium complexes containing 2,2':6',2"-terpyridine by reactions of alkoxo complexes with acids

Nitrosylruthenium complexes containing 2,2':6',2"-terpyridine (terpy) have been synthesized and characterized. The three alkoxo complexes trans-(NO, OCH3), cis-(Cl, OCH3)-[RuCl(OCH3)(NO)(terpy)]PF6 ([2]PF6), trans-(NO, OC2H5), cis-(Cl, OC2H5)-[RuCl(OC2H5)(NO)(terpy)]PF6 ([3]PF6), and [RuCl(OC3H7)(NO)(terpy)]PF6 ([4]PF6) were synthesized by reactions of trans-(Cl, Cl), cis-(NO, Cl)-[RuCl2(NO)(terpy)]PF6 ([1]PF6) with NaOCH3 in CH3OH, C2H5OH, and C3H7OH, respectively. Reactions of [3]PF6 with an acid such as hydrochloric acid and trifluoromethansulforic acid afford nitrosyl complexes in which the alkoxo ligand is substituted. The geometrical isomer of [1]PF6, trans-(NO, Cl), cis-(Cl, Cl)-[RuCl2(NO)(terpy)]PF6 ([5]PF6), was obtained by the reaction of [3]PF6 in a hydrochloric acid solution. Reaction of [3]PF6 with trifluoromethansulforic acid in CH3CN gave trans-(NO, Cl), cis-(CH3CN, Cl)-[RuCl(CH3CN)(NO)(terpy)]2+ ([6]2+) under refluxing conditions. The structures of [3]PF6, [4]PF6.CH3CN, [5]CF3SO3, and [6](PF6)2 were determined by X-ray crystallograpy.     

New chiral ruthenium(II) catalysts containing 2,6-bis(4'-(R)-phenyloxazolin-2'-yl)pyridine (Ph-pybox) ligands for highly enantioselective transfer hydrogenation of ketones

Treatment of complex trans-[RuCl(2)(eta(2)-C(2)H(4))[kappa(3)-N,N,N-(R,R)-Ph-pybox]] [(R,R)-Ph-pybox = 2,6-bis[4'-(R)-phenyloxazolin-2'-yl]pyridine] with phosphines or phosphites in dichloromethane at 50 degrees C leads to the formation of novel ruthenium(II)-pybox complexes trans-[RuCl(2)(L)[kappa(3)-N,N,N-(R,R)-Ph-pybox]] [L = PPh(3) (1 a), PPh(2)Me (2 a), PPh(2)(C(3)H(5)) (3 a), PPh(2)(C(4)H(7)) (4 a), PMe(3) (5 a), PiPr(3) (6 a), P(OMe)(3) (7 a) and P(OPh)(3) (8 a)]. Likewise, reaction of trans-[RuCl(2)(eta(2)-C(2)H(4))[kappa(3)-N,N,N-(R,R)-Ph-pybox]] with PPh(3) or PiPr(3) in refluxing methanol leads to the complexes cis-[RuCl(2)(L)(kappa(3)-N,N,N-(R,R)-Ph-pybox] [L = PPh(3) (1 b), PiPr(3) (6 b)]. No trans-cis isomerisation of complexes 1 a-8 a has been observed. Complexes 1 a-8 a, 1 b, 6 b together with the analogous trans-[RuCl(2)[P(OMe)(3)][kappa(3)-N,N,N-(S,S)-iPr-pybox]] (10 a) and the previously reported trans- and cis-[RuCl(2)(PPh(3))[kappa(3)-N,N,N-(S,S)-iPr-pybox]] (9 a and 9 b, respectively) are active catalysts for the transfer hydrogenation of acetophenone in 2-propanol in the presence of NaOH (ketone/cat/NaOH 500:1:6). cis-Ph-pybox derivatives are the most active catalysts. In particular, cis complexes 1 b and 6 b led to almost quantitative conversions in less than 5 min with a high enantioselectivity (up to 95 %). A variety of aromatic ketones have also been reduced to the corresponding secondary alcohols with very high TOF and ee up to 94 %. The overall catalytic performance seems to be a subtle combination of the steric and/or electronic properties both the phosphines and the ketones. A high TOF (27 300 h(-1)) and excellent ee (94 %) have been found for the reduction of 3-bromoacetophenone with catalyst 6 b. Reductions of alkyl ketones also proceed with high and rapid conversions but low enantioselectivities are achieved.     

Influence of the electronics of the phosphine ligands on the H-H bond elongation in dihydrogen complexes

Five new monocationic dihydrogen complexes of ruthenium of the type trans-[RuCl(eta(2)-H(2))(PP)(2)][BF(4)] (PP = bis-1,2(diarylphosphino)ethane, aryl = p-fluorobenzyl, 1a, benzyl, 2a, m-methylbenzyl, 3a, p-methylbenzyl, 4a, p-isopropylbenzyl, 5a) have been prepared by protonating the precursor hydride complexes trans-[RuCl(H)(PP)(2)] using HBF(4).OEt(2). The dihydrogen complexes are quite stable and have been isolated in the solid state. The intact nature of the H-H bond in these derivatives has been established from the short spin-lattice relaxation times (T1, ms) and observation of substantial H, D couplings in the HD isotopomers. The H-H bond distances (dHH, A) increase systematically from 0.97 to 1.03 A as the electron-donor ability of the substituent on the diphosphine ligand increases from the p-fluorobenzyl to the p-isopropylbenzyl moiety. The d(HH) in trans-[Ru(eta(2)-H(2))(Cl)((C(6)H(5)CH(2))(2)PCH(2)CH(2)P(CH(2)C(6)H(5))(2))(2)][BF(4)], 2a, was found to be 1.08(5) A by X-ray crystallography. In addition, two new 16-electron dicationic dihydrogen complexes of the type [Ru(eta(2)-H(2))(PP)(2)][OTf](2) (PP = (ArCH(2))(2)PCH(2)CH(2)P(CH(2)Ar)(2), Ar = m-CH(3)C(6)H(4-), 6a, p-CH(3)C(6)H(4)-, 7a) have also been prepared and characterized. These derivatives were found to possess elongated dihydrogen ligands.     

The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro

Two novel paullone derivatives, namely, 6-(alpha-picolylamino)-7,12-dihydroindolo[3,2-d][1]benzazepine (L1) and 9-bromo-6-(alpha-picolylamino)-7,12-dihydroindolo[3,2-d][1]benzazepine (L2), have been prepared. The reaction of cis-[RuCl2(DMSO)4] (DMSO=dimethyl sulfoxide) with L1 and L2 in a 1:1 molar ratio in dry ethanol at 50 degrees C afforded the complexes trans-[RuIICl2(DMSO)2L1] (1a) and trans-[RuIICl2(DMSO)2L2] (1b) in 26 and 30% yield, respectively. The reaction carried out from the same starting compounds in a 1:2 molar ratio at 75 degrees C led to the formation of [RuIICl(DMSO)(L1)2]Cl (2a) and [RuIICl(DMSO)(L2)2]Cl (2b) in 16 and 23% yield, correspondingly. The products were characterized by elemental analysis, one- and two-dimensional NMR spectroscopy, electrospray ionization mass spectrometry, IR spectroscopy, electronic spectra, cyclic voltammetry, and X-ray crystallography (L1, L2, 1a, and 2b). Complexes 2a and 2b exhibit remarkable antiproliferative activity in three human carcinoma cell lines, A549 (non-small cell lung carcinoma), CH1 (ovarian carcinoma), and SW480 (colon carcinoma). The novel complexes show an intercalative mode of interaction with DNA, which may render them attractive alternatives to metal compounds with a coordinative mode of interaction.     

Ruthenium(II) complexes of 2-benzoylpyridine-derived thiosemicarbazones with cytotoxic activity against human tumor cell lines

Reaction of [RuCl(3)(dppb)H(2)O] (dppb=1,4 bis(diphenylphospine)butane) with 2-benzoylpyridine thiosemicarbazone (H2Bz4DH) and its N(4)-methyl (H2Bz4M) and N(4)-phehyl (H2Bz4Ph) derivatives gave [RuCl(dppb)(H2Bz4DH)]Cl (1), [RuCl(dppb)(H2Bz4M)]Cl (2) and [RuCl(dppb)(H2Bz4Ph)]Cl (3). The cytotoxic activity of the studied compounds was tested against the MCF-7, TK-10 and UACC-62 human tumor cell lines. The precursor [RuCl(3)(dppb)H(2)O] exhibits cytocidal activity against the tree cell lines. H2BzDH, H2Bz4M, and [RuCl(dppb)(H2Bz4M)]Cl (2) show a selective cytocidal effect against the UACC-62 cell line which makes them the most promising compounds.